Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DWKI46
|
|||
| Drug Name |
PB006
|
|||
| Synonyms |
Natalizumab Biosimilar
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Crohn disease [ICD-11: DD70; ICD-10: K50, K50.9; ICD-9: 555] | Phase 3 | [1] | |
| Company |
Polpharma Biologics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04115488) Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri? in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS). U.S.National Institutes of Health. | |||
| REF 2 | Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial. JAMA Neurol. 2023 Mar 1;80(3):298-307. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.